FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 559 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... September 25, 2025 Cross-Border Network of European Specialists Provides New Treatment Options For Women... June 17, 2024 Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... December 12, 2019 ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy June 6, 2024 Load more HOT NEWS Cancer in My Community: Improving Access to Palliative Care in Indonesia FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... New independent tobacco review sets roadmap for a smokefree England for... FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours
